We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Blood Test Helps Diagnose Inaccessible Brain Tumors

By LabMedica International staff writers
Posted on 03 Jan 2023

Worldwide, brain cancer is the 12th most lethal cancer, and each year, more than 250,000 adults die due to the disease. More...

Diagnosis of brain tumors is resource-intensive, risk-prone and brain biopsies are impossible to perform in almost 40% of advanced cases. Presently, no blood test is available for diagnosing brain cancers, and doctors have to rely on complex surgical procedures to obtain tumor tissue for histopathological evaluation. Now, a new blood test can detect the cells released from the brain tumor that are extremely rare and hard to detect, enabling early diagnosis and treatment.

The TriNetra-Glio liquid biopsy from Datar Cancer Genetics Inc. (London, UK) is a blood test to help in the diagnosis of brain tumors where a conventional biopsy is not possible. The test requires only a blood draw and can help detect brain tumors in asymptomatic adult males and females based on the presence of Circulating Tumor Cells (CTCs). The test evaluates blood samples for the presence of CTCs which may be further analyzed to determine the organ or tissue of origin. The TriNetra-Glio liquid biopsy requires 15 ml blood and is indicated for patients where a brain biopsy, although necessary, cannot be performed or has been unsuccessful. In a prospective, blinded study, the test has shown very high accuracy in detecting malignant brain tumors. The TriNetra-Glio liquid biopsy has received Breakthrough Device Designation from the US FDA after previously receiving CE certification and is already available to patients as Trublood-CNS.

"The breakthrough designation is a recognition of the potential benefits of TriNetra-Glio in the clinical setting. The test can help individuals where a brain biopsy or surgical resection of the tumor is not possible due to the location of the tumor or other constraints. With our proprietary CTC-enrichment and detection technology, a diagnosis of inaccessible tumors will become possible through a risk-free and patient-friendly blood test," said Dr. Vineet Datta, Executive Director of the company.

Related Links:
Datar Cancer Genetics Inc.


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Quality Control Material
Multichem ID-B
New
Drug Test Kit
DrugCheck 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.